EXELIXIS INC

Exelixis insider Mary Beckerle’s August sale is a routine liquidity move, not a sign of waning confidence – investors can still see long‑term upside in its biotech pipeline.

Insider buying of 8,367 Exelixis shares signals confidence in upcoming oncology drug approvals, hinting at potential upside for shareholders.

Exelixis insider activity: David Johnson’s new 19,133‑option grant shows bullish confidence amid market caution—what it means for investors and the company’s future.

Exelixis insider sale: 32,110 shares by EVP Haley Patrick J. shows routine RSU liquidity, not a warning—company remains solidly bullish with steady growth.

Michael Morrissey’s rare charitable sale of 109,676 Exelixis shares—while keeping a 1.7% stake—signals strong executive confidence, boosts investor sentiment, and highlights leadership’s philanthropy amid a positive analyst upgrade and a robust biot…

Julie Smith’s bulk buys at Exelixis reveal insider confidence – buy‑back at $18‑$19, well below market, signaling potential upside amid exec sales and a biotech pipeline poised for milestones.